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Abstract:
Phosphomevalonate kinase (PMK) phosphorylates mevalonate-5phosphate (M5P) in the mevalonate pathway, which is the sole source of
isoprenoids and steroids in humans. We have identified new PMK inhibitors
with virtual screening, using Autodock. Promising hits were verified and their
affinity measured using NMR-based 1H-15N Heteronuclear Single Quantum
Coherence (HSQC) chemical shift perturbation and fluorescence titrations.
Chemical shift changes were monitored, plotted, and fitted to obtain
dissociation constants (Kd). Tight binding compounds with Kd’s ranging from
6–60 µM were identified. These compounds tended to have significant polarity
and negative charge, similar to the natural substrates (M5P and ATP). HSQC
crosspeak changes suggest that binding induces a global conformational
change, such as domain closure. Compounds identified in this study serve as
chemical genetic probes of human PMK, to explore pharmacology of the
mevalonate pathway, as well as starting points for further drug development.
Keywords: Human phosphomevalonate kinase, inhibitors, virtual screening,
molecular docking.

Introduction
Phosphomevalonate kinase (PMK), a mevalonate pathway
enzyme, catalyzes a key phosphorylation step in isoprenoid/sterol
biosynthesis, and provides a variety of products that are necessary for
normal cellular growth and signaling, such as cholesterol, bile acids,
heme A, dolichol, and ubiquinone.[1] Due to the central role of
isoprenoids, imbalances in isoprenoid synthesis and utilization can lead
to cellular dysfunction and disease. [2–4] Inhibitors of two enzymes in
this pathway are of particular clinical relevance. The statins, a large
class of hydroxymethyl glutaryl-CoA reductase (HMG CoA) inhibitors,
are widely used to treat elevated cholesterol levels.[5] And,
bisphosphonate inhibitors of farnesylpyrophosphate synthase are used
to treat metabolic bone disease.[6] However, the mechanism and
pharmacology of other potentially druggable enzyme targets in this
pathway are less well-characterized, so additional studies and
pharmacological probes are needed.[7]
PMK in comprised of two domains. The larger ATP-binding
domain (CORE, Fig. 1) is composed of a five stranded parallel β-sheet
interweaved with three α-helices. The mevalonate- 5-phosphate (M5P)
domain (Substrate, Fig. 1) is composed of loop regions and two-αBiochemical and Biophysical Research Communications, Vol. 430, No. 1 (January 2013): pg. 313-319. DOI. This article is ©
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helices. PMK catalyzes the transfer of a phosphoryl group from
adenosine-5'-triphosphate (ATP) to M5P, resulting in mevalonate-5pyrophosphate and adenosine diphosphate (ADP). [8–12] While details
of the protein motion that occurs during catalysis remain unclear, the
LID (Fig. 1) region is likely involved in an opening and closing motion
to permit the binding and release of substrates.[13–15] Herdendorf
and Miziorko investigated the functional role of conserved basic
residues in human PMK and suggested that R110 was important for
human PMK catalysis.[16] R111 and R84 are situated close to the
“Walker B” motif and seem to be involved in binding M5P.[16]
Residues K100 and K101 are in close proximity to the ATP binding site,
and likely stabilize the transition state for conversion of ATP to
ADP.[17, 18]
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Fig. 1

Crystal structure of human PMK (PDB ID 3ch4)[22] showing the different

functionally relevant regions of the protein. The LID region caps the active site where
phosphate transfer occurs, and contains catalytic residues needed for stabilizing the
negative charge buildup in the phosphate transfer transition state. The CORE and
Substrate domains are proposed to participate in significant domain rearrangements
upon binding the substrates M5P and MgATP.[15]

In this study, we aim to identify novel inhibitors with high
affinity for human PMK, based on our understanding of important
protein-ligand interactions that involve the abovementioned basic
residues. These inhibitors could provide clues as to the relative
importance of binding interactions, and could themselves be useful as
chemical probes of function (ex. in cellular assays or in vivo).
Molecular docking has become an important early-stage method for
finding novel inhibitors, when a protein structure is available.[19, 20]
The process allows a large number of chemicals to be tested quickly in
silicoand promising chemicals can then be prioritized for experimental
verification of binding in vitro.[21] Given the high false-positive rate of
docking predictions, it is crucial to verify predicted binding affinity
using experimental assays. Two PMK structures have been published,
allowing for docking-based identification of inhibitors.[2, 22]
NMR methods allow for a comprehensive monitoring of the
effects of ligand binding, by providing chemical shift change
measurements that reflect structural changes throughout the entire
protein. Of particular interest, the 1H-15N HSQC experiment can
provide an effective method for monitoring changes to a protein
structure upon substrate or inhibitor addition, based on changes to 1H
and 15N chemical shifts of all the protein backbone amides.[23] Since
PMK is known to undergo substrate-induced structural changes[24],
solution NMR techniques are well-suited to study interactions involving
the human PMK/ligand complexes, which may also involve ligandinduced global structural rearrangements, such as the domain closure
that substrate binding induces. Using molecular docking, solution NMR
techniques, and fluorescence titrations, we identified novel inhibitors of
human PMK. By monitoring 1H-15N HSQC chemical shift perturbations,
site specific molecular interactions were identified and characterized.
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Materials and Methods
Virtual Screening Protocol
Chemicals to be docked were sourced from two datasets: an inhouse collection of 10,000 drug-like compounds, previously purchased
or synthesized for kinase and oxidoreductase studies, and
Chemiebase, a Thai Natural Products collection containing 1,000
structures.[25, 26] Before docking, ligands were adjusted to the
proper protonation state at pH 7.4 by Pipeline Pilot, ver. 7.4 [27], and
three-dimensional structures were calculated using Corina.[28]
Molecular docking experiments were performed with AutoDock
4.2.[29–31]
The structure of human PMK (PDB ID: 3CH4) was obtained from
the Protein Data Bank.[22] Gasteiger charges and hydrogens were
added using AutoDock Tools (ADT). The docking grid, centered on the
M5P binding pocket, was also prepared using ADT with a grid box
created using 60 × 60 × 60 points and a resolution of 0.375 Å.

Protein Expression and Purification
Human PMK is a 192-residue protein with a molecular weight of
22.0 kDa. To aid in purification, a hexa-histidine tag was added at the
N-terminus resulting in a total molecular weight of 24.2 kDa. Human
PMK cDNA was purchased from OriGene, subcloned into the pET15b
expression plasmid, expressed, and purified as described
previously.[8] Briefly, the expression plasmid was transformed into
Escherichia coli BL21 (DE3) Rosetta cells(Novagen) which encoded
human PMK. Then, cells were grown in 1 L of Luria-Bertani(LB) media
containing ampicillin (amp) and chloramphenicol (chl) until the optical
cell densities at 600 nm (OD600) reached 0.7. The cells were harvested
by centrifugation for 15 minutes at 6000xg. These cells were
suspended in minimal media with amp-chl antibiotics supplemented
with 15N-NH4Cl (Sigma Aldrich) as the lone source of nitrogen.[32]
Cells were allowed to acclimate for an hour, and then they were
induced with 1 mM IPTG. Cells were harvested 4h after induction by
centrifugation. Cell pellets were re-suspended in a buffer containing 50
mM potassium phosphate, 5 mM imidazole, 5% glycerol, 1mM
phenylmethanesulfonylfluoride (PMSF), and 300 mM NaCl at pH 7.8.
Biochemical and Biophysical Research Communications, Vol. 430, No. 1 (January 2013): pg. 313-319. DOI. This article is ©
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Cells were lysed by passage through in a microfluidizer at ~17 kpsi.
The lysate was clarified by centrifugation at 15,000 rpm for 30
minutes, and the supernatant loaded onto 1 mL of a Ni-Sepharose
Fast-Flow resin (GE Healthcare). The column was washed with the 50
mM phosphate buffer until A280 < 0.005, and the protein was eluted
using the same buffer supplemented with 300 mM imidazole. Protein
concentration was determined spectrophotometrically using an
extinction coefficient (ε280) of 32,290 M−1 cm−1 calculated with ExPASy
ProtParam and the amino acid sequence.[33]

NMR Sample Preparation and Spectroscopy
Protein was concentrated to 400–600 µM by using a 10 kDa
cutoff centricon (AMD Millipore) filter and exchanged into a buffer
containing 20 mM potassium phosphate, 5 mM dithiothreitol (DTT),
100 mM potassium chloride, 10% glycerol, 0.02% sodium azide, and
10% D2O, at pH 6.5. All screened compounds were dissolved in d6dimethyl sulfoxide (DMSO) to a concentration of 5 mM. Titrations were
performed using 100 µM increments. Spectra were compared to
control experiments of PMK and d6-DMSO (Supp. Fig. 2). Crosspeaks
without a d6-DMSO effect 1H-15N HSQC chemical shifts were monitored
and used to calculate Kd values. NMR experiments were performed at
25 °C using a Varian 600 MHz NMR system at 599.515 MHz using a
triple resonance probe, with actively shielded Z-gradients. NMR data
were processed and visualized by using NMRPipe[34] and analyzed
with NMRview.[35] Dissociation constants (Kd) were calculated by from
chemical shift changes resulting from conversion of free PMK, to the
various bound states, as described previously.[15] The peaks that
were monitored were in fast exchange in both 1H and 15N dimensions.
Chemical-shift perturbations from NMR titrations were quantified using
Eq. 1,

Then, the Kd value was determined by plotting and fitting (GraphPad
Prism ver. 4.00[36]) the chemical shift changes (Δshiftobs) as a
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function of the concentration of protein and ligand, using the quadratic
equation in Eq. 2,

where L0 and P0 are the total ligand concentration at a particular point
and protein concentration, respectively, while Δshiftmax is the
maximum chemical shift change observed for the particular peak of
interest.

Fluorescence Titration
Fluorescence titrations were performed at 25 °C, using a Jasco
FP-6500 spectrofluorotometer. The fluorescence emission of human
PMK was measured in a total volume of 0.4 mL of buffer containing 20
mM potassium phosphate, 5 mM DTT, 100 mM potassium chloride,
10% glycerol at pH 6.5 and 5 µM human PMK. Excitation was
performed at 295 nm, and emission was recorded at 300–400 nm. To
determine the Kdthe difference in intensity between bound and free
states at each data point were monitored and fitted as a function of
ligand concentration to the one-site specific binding equation using
GraphPad Prism ver. 4.00.[36]

Results
Chemicals from the two sources (synthetic and natural
products) were prioritized for experimental screening based upon
docking scores and cluster size, from Autodock 4.2 virtual screening.
In total, 26 compounds were identified and then screened using NMR
1
H-15N HSQC titration experiments; and, chemical shift changes were
monitored upon addition of ligand aliquots. Four of these 26 chemicals
(15%) showed measurable affinity for PMK in the NMR assay, so
fluorescence titrations were also performed for these four compounds
to confirm their binding to PMK. Binding affinities for these
Biochemical and Biophysical Research Communications, Vol. 430, No. 1 (January 2013): pg. 313-319. DOI. This article is ©
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experiments are summarized in Table 1 and binding fits are provided
in Supp. fig. S1 and S2.

Table 1

Predicted and experimental binding affinity for compounds identified using

Autodock 4.2 to dock compounds into human PMK. NMR and fluorescence techniques
were then used to experimentally verify binding, and determine dissociation constants
Biochemical and Biophysical Research Communications, Vol. 430, No. 1 (January 2013): pg. 313-319. DOI. This article is ©
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(Kd values).
aThe NMR fit was not reliable because in addition to a specific binding event that
seems to occur at low concentrations, there is also a non-specific effect that does not
plateau.

In an attempt to illustrate the location of inhibitor binding,
chemical changes were mapped onto the human PMK crystal structure
(PDB ID: 3ch4). In Figure 2the 2D 1H-15N HSQC spectra and chemical
shift mapping are shown for 3 the chemicals sourced from the in house
collection of synthetic compounds. Figure 3 depicts this information for
the hit obtained from the Chemibase collection of Thai natural
products.
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Fig. 2

Chemical shift perturbations due to binding of the inhibitors identified from

the synthetic compound collection. 1H-15N HSQC spectra chemical shifts are mapped
onto the human PMK crystal structure [22], with the predicted binding pose from
Autodock for each ligand; chemical shift changes are color-coded such that red is a
large (> 0.09 ppm) chemical shift change, yellow is a medium (0.05–0.09 ppm)
chemical shift change, and blue indicates small or no chemical shift change. Inset
panels show chemical shift changes that were used to fit binding data (Eq. 1 and Eq.
2). Panels A and B are for compound CSDDD_1633, C and D are for compound
CSDDD_2260, and E and F are for compound CSDDD_2419.

Fig. 3

Chemical shift perturbations due to binding of an inhibitor (luteolin) from the

Thai Natural Products compound collection, Chemiebase.[25, 26]. 1H-15N HSQC
spectra chemical shifts (Panel B) are mapped onto the human PMK crystal structure
(Panel A) [22], with the predicted binding pose from Autodock shown; chemical shift
changes are color-coded such that red is a large (> 0.09 ppm) chemical shift change,
yellow is a medium (0.05–0.09 ppm) chemical shift change, and blue indicates small
or no chemical shift change. The inset panel shows chemical shift changes that were
used to fit binding data (Eq. 1 and Eq. 2).

Discussion
The studies presented herein identified four novel inhibitors of
PMK, which could lead to pharmacologically useful chemical probes or
perhaps even drug leads that target the mevalonate pathway via
inhibition of PMK. Molecular docking provided a prioritized listing of
chemicals with potential affinity for PMK, with chemicals selected from
two chemical collections, an inhouse collection of synthetic
compounds, and Chemiebase[25, 26], a Thai natural product
collection. Hits were identified from each chemical source and
experimentally validated using NMR 1H-15N HSQC and fluorescence
Biochemical and Biophysical Research Communications, Vol. 430, No. 1 (January 2013): pg. 313-319. DOI. This article is ©
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experiments. Of compounds predicted to bind to PMK using Autodock,
15% were verified by two methods (NMR and fluorescence) as being
actual ligands for PMK. It is noteworthy that NMR titration methods are
inherently limited in that they do not provide accurate measures of Kd
values, when the Kd value is much less than the protein concentration
that must be used in the experiment (which is itself limited by
experimental sensitivity of the HSQC experiment). In these situations,
data fitting to determine Kd must be done using a quadratic equation
(Eq. 2), and errors increase as Kd≪[protein]. But, NMR chemical shift
perturbation data will confirm binding and provide an upper limit for a
Kd even in these situations, and more accurate Kd values can then be
obtained with fluorescence titrations.
Docking and subsequent titrations (NMR and fluorescence)
identified three synthetic compounds from the in-house compound
collection (CSDDD library) with Kd values in the 12–30 µM range
(fluorescence), Table 1. A common feature of these compounds is the
presence of negative charges, which could mimic the negative charge
on the phosphate groups of the natural substrates, ATP and M5P.
Indeed, Autodock 4.2 placed these ligands (Fig. 2A, 2C, 2E) near the
LID and CORE regions of the protein, close to the highly basic region of
the known binding site for the natural substrates. Likely, these
inhibitors are taking advantage of the strong electrostatic interactions
with positively charged amino acids in the vicinity, including K17, R18,
K19, K22, R138, and R141. Each of the three in-house collection
inhibitors bind tightly to human PMK (Table 1) and these affinities
favorably compare to those of the natural substrates ATP (29 ± 6 µM)
and ADP (19.9 ± 9.0 µM).[15] When plotting the chemical shift
perturbations for two chemicals (Supp. Fig. S3), complex binding was
observed that could not be accounted for by the quadratic binding
model used herein. In the case of CSDDD_2419, (Supp. fig. S3A) the
binding fit showed a nonspecific effect in addition to an initial binding
event that appears to be saturable. These additional effects can be
detected using NMR titrations, because NMR is adept at detecting
weakly interacting ligands; thus, there is a need for additional
fluorescence titrations to verify the presence of saturable ligandprotein binding, and to obtain more accurate Kd values when
Kd≪[protein].
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NMR titrations can also provide structural information, based on
location of the perturbed amino acid in the 3D structure of the protein,
which corresponds to the crosspeak that is perturbed (if chemical shift
assignments are available for the protein). Monitoring of chemical shift
perturbations of crosspeaks in 2D 1H-15N HSQC spectra of PMK
indicates there has been substantial movement of residues in the
CORE and LID regions shown in Fig 2.[15] CSDDD_1633 and
CSDDD_2260 both perturb the chemical shift of D163, an important
hinge residue between the LID and CORE regions.[15] Also, ligandPMK binding produced chemical shift perturbations outside of the
binding site, suggesting a conformational changes, such as those that
could result from motion around the hinge residue between domains,
as we have reported previously.[15] Similar chemical shift
perturbations are seen in this study to those that we have reported
previously for ATP binding, both at the hinge and outside the ATP
binding site, further suggesting that the in-house synthetic compounds
are binding similarly to ATP.
Consistent with their binding in a highly basic pocket (intended
to accommodate phosphates), all three of the compounds identified
have at least two formal negative charges, either on sulfonate groups
(CSDDD_1633 and CSDDD_2419) or carboxylic acids (CSDDD_2260).
Recently, we observed that molecules with sulfonates could function as
biomimics for naturally occurring negatively charged ligands with
phosphates, sulfates, or posttranslationally modified residues (either
phosphorylated or sulfated).[37] Compounds CSDDD_1633 and
CSDDD_2419 also contain phenolic groups that would be expected to
have low pKa’s, based on potential for resonance delocalization of
negative charge (though an azo group or into a quinine carbonyl). This
would put an additional negative charge on these molecules. Thus, all
inhibitors are highly charged, making them suitable mimics of the PMK
substrates which are also rich with negative charges.
Docking and subsequent titration studies also identified a
natural product inhibitor, luteolin, a flavanoid, from the Chemibase
collection. Luteolin has modest affinity for PMK, with a Kd of 61 µM.
While it appears that luteolin exhibits no charge, this is probably not
accurate. As for two of the compounds reported above, luteolin
contains phenolic groups that are likely to be readily ionized, due to
resonance delocalization into the quinine carbonyls. Indeed, the
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phenolic quinone substructure in in CSDDD_1633 is similar to the
corresponding substructure in luteolin. Chemical shift perturbation
mapping for this compound (Fig. 3) is strikingly different from the inhouse compounds. It is therefore possible that luteolin is binding
differently than the in-house synthetic chemicals. But, luteolin does
cause a large chemical shift perturbation to the active site D163, as
expected.[15] Interestingly, luteolin has been reported to show a wide
range of biological effects including cardiovascular protection [38], but
it is not clear what protein targets are responsible for this effect. It is
possible that binding to PMK may at least contribute to the favorable
cardiovascular effects of luteolin.

Conclusion
In summary, we have identified novel inhibitors of PMK, which
possess significant negative charge that is suitable for binding to the
highly basic PMK active site. Using virtual screening to identify
potential inhibitors, and NMR and fluorescence experiments to verify
binding, we found that docking yielded a hit rate of 15% and identifies
reasonably potent PMK inhibitors with Kd values in the 6–60 µM range.
These molecules could be useful to investigators as chemical genetic
probes or as starting points in further drug and inhibitor design
studies.

Highlights


Natural and synthetic inhibitors of human phosphomevalonate
kinase identified.



Virtual screening yielded a hit rate of 15%, with inhibitor Kd’s of
10–60 µM.



NMR studies indicate significant protein conformational changes
upon binding.
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Supplementary Material
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Supplementary information
Supplemental Figure Legends
Supplemental figure S1. Fitting of fluorescence data for ligands
identified in this study. Plots are organized as such: CSDDD_1633 is
panel A, CSDDD_2260 is panel B, CSDDD_2419 is panel C, and
luteolin is panel D. Data were fitted to the one-site specific binding
equation in GraphPad Prism ver. 4.00:

Supplemental figure S2. Fitting of data for chemical shift
perturbation for CSDDD_1633 (panel A) by monitoring G177 and
CSDDD_2260 (panel B) by monitoring T128. Lines represent fits to
the quadratic equation (see equation 2 Materials and Methods).

Supplemental figure S3. Plots of NMR data for chemical shift
perturbation of CSDDD_2419 (panel A) and luteolin (panel B). In
addition to what may be a saturable binding event at lower
concentration (highlighted by the boxed regions), there is also a
nonsaturable effect at higher concentrations – so, NMR titration data
could not be fitted to the quadratic model used herein.

Supplemental figure S4. 1H-15N HSQC spectra of PMK upon
exposure to increasing concentrations of d6-DMSO. Red peaks are free
PMK, grey peaks 5% d6-DMSO and black peaks are 10% d6-DMSO.
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Supplemental Figures
Supplemental figure S1.

Supplemental figure S2.
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Abbreviations
PMK

phosphomevalonate kinase

M5P

mevalonate-5-phosphate

HSQC

heteronuclear single quantum coherence

1

HMG CoA hydroxymethyl glutaryl-CoA reductase
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